Researchers plan to adopt the Promega LMR MSI Analysis System for endometrial, prostate, and other non-GI cancers – the review by BIOMEDICA CRO.
Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors.
A study published in the Journal of Molecular Diagnostics states that the researchers will continue using the current gold standard for PCR-based microsatellite instability (MSI) testing, the Promega MSI Analysis System, Version 1.2, for detecting MSI in colorectal cancer, but they plan to adopt the Promega LMR MSI Analysis System for endometrial, prostate and other non-GI cancers.
Recently, MSI status has been rediscovered as a biomarker for the immunotherapeutic response, making MSI status an increasingly relevant tool in genetic- and immuno-oncology research.
The research group led by Dr. James Eshleman, M.D., Ph.D. validated the LMR MSI panel using colorectal, endometrial, and prostate tumor samples, as well as a variety of other tumor samples with inconclusive results in previous MSI testing.
Statistics for the LMR MSI panel include:
• Colorectal cancer: 100% accuracy, 100% clinical sensitivity, 100% clinical specificity
• Endometrial cancer: 98% accuracy, 98% clinical sensitivity, 100% clinical specificity
• Prostate cancer: 75% clinical sensitivity
• Other cancers: 100% concordance between LMR MSI and MSI V1.2 in 22 samples previously designated MSI-High
Dr.Jeff Bacher, Study Co-Author and Senior Research Scientist, Promega Corporation: “The new LMR panel clearly offers unique benefits in certain cancer types. These results are encouraging for the detection of microsatellite instability in samples that were previously difficult or impossible.”
Please follow the link for more info.
According to this study, we definitely need to continue researching and the collaboration between scientists and biospecimen providers is the best way to improve human health and wellbeing.
Our team has already collected more than 84000+ biospecimens through a broad network of partnered hospitals in Ukraine and supplied them globally to scientists from different pharmaceutical companies and research centers.
We at BIOMEDICA CRO are able to support scientists in a broad range of oncological conditions, including colorectal, endometrial, prostate, and other types of cancer. Kindly review our page with relevant biospecimens options.
BIOMEDICA CRO is honored to participate in preclinical trials, research on new biomarkers and screening tests. We are ready to collect high-quality human biospecimens to provide scientists with all needed samples and associated data for their studies. Please email us to start our collaboration: office@biomedica-cro.com.
